A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

November 1, 2016 updated by: Hoffmann-La Roche

A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.

This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

624

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • BA
      • Salvador, BA, Brazil, 40301-500
    • GO
      • Goiania, GO, Brazil, 74093-040
    • MG
      • Belo Horizonte, MG, Brazil, 30150-270
    • PR
      • Curitiba, PR, Brazil, 80240-280
    • RJ
      • Rio de Janeiro, RJ, Brazil, 22270-060
    • RS
      • Pelotas, RS, Brazil, 96030-002
      • Porto Alegre, RS, Brazil, 90035-003
    • SP
      • Sao Paulo, SP, Brazil, 04044-000
      • Sao Paulo, SP, Brazil, 05403-010
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4Z6
      • Medicine Hat, Alberta, Canada, T1B 4E7
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 3P1
      • Victoria, British Columbia, Canada, V8R 4Z3
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2E2
    • Ontario
      • Burlington, Ontario, Canada, L7R 4E2
      • Hamilton, Ontario, Canada, L8N 3K7
      • Mississauga, Ontario, Canada, L5M 4N4
    • Quebec
      • Montreal, Quebec, Canada, H3A 1A1
      • Montreal, Quebec, Canada, H1N 3M5
      • Verdun, Quebec, Canada, H4H 1R3
  • Chile
      • San Miguel, Chile, 8900000
      • Santiago, Chile
      • Santiago, Chile, 7500710
      • Santiago, Chile, 7501126
      • Santiago, Chile, 8050000
      • Santiago, Chile, 8320000
      • Valdivia, Chile, 5090000
  • Germany
      • Berlin, Germany, 10117
      • Bochum, Germany, 44805
      • Freiburg, Germany, 79104
      • Hamburg, Germany, 20246
      • Koeln, Germany, 50937
      • Muenchen, Germany, 81675
      • München, Germany, 80336
      • Nürnberg, Germany, 90402
  • Latvia
      • Daugovpils, Latvia, LV-5417
      • Jelgava, Latvia, LV-3008
      • Liepaja, Latvia, LV 3401
  • Lithuania
      • Kaunas, Lithuania, 50009
      • Kaunas, Lithuania, 48259
      • Kaunas, Lithuania, 44279
      • Kaunas, Lithuania, 53136
      • Silute, Lithuania, 99142
      • Vilnius, Lithuania, 07156
      • Vilnius, Lithuania, 10204
  • Netherlands
      • Assen, Netherlands, 9400 RA
      • Groningen, Netherlands, 9713 GZ
      • Groningen, Netherlands, 9700 AB
  • Poland
      • Choroszcz, Poland, 16-070
      • Kielce, Poland, 25-103
      • Lublin, Poland, 20-015
      • Lublin, Poland, 20-045
      • Lublin, Poland, 20-080
      • Piekary Slaskie, Poland, 41-940
      • Skorzewo, Poland, 60-185
      • Tuszyn, Poland, 95-080
      • Warszawa, Poland, 02-957
  • Slovakia
      • Bojnice, Slovakia, 972 01
      • Bratislava, Slovakia, 820 07
      • Bratislava, Slovakia, 851 01
      • Rimavska Sobota, Slovakia, 97912
      • Svidnik, Slovakia, 089 01
  • Spain
      • Barcelona, Spain, 08036
      • Barcelona, Spain, 08304
      • Barcelona, Spain, 08830
      • Madrid, Spain, 28040
      • Madrid, Spain, 28009
      • Salamanca, Spain, 37007
      • Zamora, Spain, 49021
    • Asturias
      • Oviedo, Asturias, Spain, 33011
  • Taiwan
      • Hualian Town, Taiwan, 970
      • Kaohsiung, Taiwan, 80276
      • Taichung, Taiwan, 407
      • Tainan, Taiwan, 704
      • Tainan County, Taiwan, 717
      • Taipei, Taiwan, 110
      • Taipei, Taiwan, 00112
  • Turkey
      • Ankara, Turkey, 06100
      • Diyarbakir, Turkey, 21280
      • Gaziantep, Turkey, 27310
      • Istanbul, Turkey, 34390
      • Istanbul, Turkey, 34736
      • Manisa, Turkey, 45010
  • Ukraine
      • Dnipropetrovsk, Ukraine, 49005
      • Donetsk, Ukraine, 83008
      • Glevakha Kyviv region, Ukraine, 08631
      • Kharkiv, Ukraine, 61068
      • Kyiv, Ukraine, 02660
      • Kyiv, Ukraine, 04080
      • Lviv, Ukraine, 79021
      • Odessa, Ukraine, 65006
      • Vinnytsya, Ukraine, 21005
  • United States
    • California
      • Carson, California, United States, 90746
      • Oceanside, California, United States, 92056
      • San Diego, California, United States, 92123
      • San Diego, California, United States, 92121
    • Connecticut
      • Hartford, Connecticut, United States, 06106
      • Norwalk, Connecticut, United States, 06851
    • Florida
      • North Miami, Florida, United States, 33161
    • Georgia
      • Atlanta, Georgia, United States, 30328
    • Illinois
      • Chicago, Illinois, United States, 60612
      • Hoffman Estates, Illinois, United States, 60169
      • Joliet, Illinois, United States, 60435
    • Louisiana
      • Lake Charles, Louisiana, United States, 70601
      • Shreveport, Louisiana, United States, 71104-2136
    • Missouri
      • St. Louis, Missouri, United States, 63128
    • Nebraska
      • Omahac, Nebraska, United States, 68131
    • New York
      • Cedarhurst, New York, United States, 11516
      • Jamaica, New York, United States, 11418
      • Rochester, New York, United States, 14623
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18104
      • Norristown, Pennsylvania, United States, 19403
      • Philadelphia, Pennsylvania, United States, 19139

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult patients, aged 18 years and above
  • Diagnosis of schizophrenia of paranoid, disorganized, residual, undifferentiated or catatonic subtype
  • Predominant negative symptoms
  • With the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotics (treatment with a maximum of two antipsychotics)

Exclusion Criteria:

  • Evidence that patient has clinically significant, uncontrolled and unstable disorder (e.g. cardiovascular, renal, hepatic disorder)
  • Body Mass Index (BMI) of <17 or >40 kg/m2
  • Depressive symptoms, defined as a score of 9 or greater on the Calgary Depression Rating Scale for Schizophrenia (CDSS)
  • A severity score of 3 or greater on the Parkinsonism item of the ESRS-A (Clinical Global Impression, Parkinsonism)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
Drug: bitopertin [RO4917838]
Oral dose level 1, once a day for 52 weeks
Drug: bitopertin [RO4917838]
Oral dose level 2, once a day for 52 weeks
Experimental: 2
Drug: bitopertin [RO4917838]
Oral dose level 1, once a day for 52 weeks
Drug: bitopertin [RO4917838]
Oral dose level 2, once a day for 52 weeks
Placebo Comparator: 3
Drug: Placebo
Oral doses, once a day for 52 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Efficacy (PANSS negative symptoms factor score)
Time Frame: Week 24
Week 24
Safety (incidence of adverse events)
Time Frame: Week 24
Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hoffmann-La Roche

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2010

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

July 1, 2014

Study Registration Dates

First Submitted

August 30, 2010

First Submitted That Met QC Criteria

August 30, 2010

First Posted (Estimate)

September 1, 2010

Study Record Updates

Last Update Posted (Estimate)

November 2, 2016

Last Update Submitted That Met QC Criteria

November 1, 2016

Last Verified

November 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WN25309
  • 2010-020467-21

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on bitopertin [RO4917838]

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe